{
    "clinical_study": {
        "@rank": "139415", 
        "arm_group": [
            {
                "arm_group_label": "FK949E low dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "FK949E middle dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "FK949E high dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "In this study, FK949E or placebo will be administered orally for 6 weeks to major depressive\n      disorder patients with lack of response to existing antidepressants, with the aim of\n      evaluating the efficacy of FK949E and dose-response in the three FK949E dose groups based on\n      changes in Montgomery-Asberg Depression Rating Scale (MADRS) scores. The safety and\n      pharmacokinetics of FK949E will also be evaluated."
        }, 
        "brief_title": "Study to Evaluate the Effect and Safety of FK949E in Major Depressive Disorder Patients", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of major depressive disorder as specified in the DSM-IV-TR with the use of\n             the Mini-International Neuropsychiatric Interview (M.I.N.I.)\n\n          -  Documented appropriate treatment history (i.e., lack of response to treatment at\n             labeled dosage for at least 4 weeks) for the current major depression episode with an\n             antidepressant other than that used concomitantly with the study drug\n\n          -  The Hamilton Depression Rating Scale (HAM-D17) total score of 20 points or more and\n             HAM-D17 depressed mood score of 2 points or more\n\n        Exclusion Criteria:\n\n          -  Concurrent or previous history of DSM-IV-TR Axis I disorders, except major depressive\n             disorder, within the last 6 months before informed consent\n\n          -  Concurrence of DSM-IV-TR Axis II disorder that is considered to greatly affect\n             patient's current mental status\n\n          -  The duration of the current major depression episode is shorter than 4 weeks or\n             longer than 24 months at informed consent\n\n          -  History of dependence of substances other than caffeine and nicotine or history of\n             abuse or dependence of alcohol\n\n          -  The HAM-D17 suicide score of 3 points or more, history of suicide attempt within the\n             last 6 months before informed consent, or the risk of suicide in the investigator's\n             or subinvestigator's opinion\n\n          -  Concurrent or previous history of diabetes mellitus. HbA1c levels of 6.1% (JDS\n             values) or more within the past 2 months\n\n          -  Electroconvulsive therapy within the last 62 days before primary registration (within\n             the last 90 days before secondary registration)\n\n          -  Treatment with a depot antipsychotic within the last 28 days\n\n          -  Documented or suspected (to be a carrier of) conditions such as renal failure,\n             hepatic failure, serious cardiac disease (or current use of antiarrhythmic drugs),\n             hepatitis B, hepatitis C, or acquired immunodeficiency syndrome (AIDS)\n\n          -  Concurrence of uncontrolled hypertension (defined as a systolic blood pressure of 180\n             mmHg or more, or a diastolic blood pressure of 110 mmHg or more at primary\n             registration) or unstable angina that may worsen with the study or may affect the\n             study results based on the clinical judgment of the investigator or subinvestigator\n\n          -  Concurrence of hypotension (defined as a systolic blood pressure of less than 100\n             mmHg at primary registration) or orthostatic hypotension\n\n          -  Concurrence of malabsorption syndrome, hepatic disease, or other conditions that may\n             affect the absorption and/or metabolism of the study drug\n\n          -  Concurrent or previous history of cerebrovascular disease or transient ischemic\n             attack (TIA)\n\n          -  Known hypersensitivity to quetiapine or any component of FK949E tablets"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "172", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01725282", 
            "org_study_id": "6949-CL-0005"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "FK949E low dose", 
                    "FK949E middle dose", 
                    "FK949E high dose"
                ], 
                "description": "oral", 
                "intervention_name": "FK949E", 
                "intervention_type": "Drug", 
                "other_name": "quetiapine"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "oral", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "FK949E", 
            "patients"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hokkaidou", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kantou", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kinki", 
                        "country": "Japan"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "Phase II Study of FK949E -Placebo-controlled, Double-blind, Parallel-group Comparative Study in Major Depressive Disorder Patients With Lack of Response to Existing Antidepressants-", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Montgomery-Asberg Depression Rating Scale (MADRS) is a ten-item diagnostic questionnaire to measure the severity of depressive episodes in patients with mood disorders.", 
            "measure": "Changes in Montgomery-Asberg Depression Rating Scale (MADRS) total scores", 
            "safety_issue": "No", 
            "time_frame": "Baseline and the final assessment point during the treatment period. Treatment period is for 6 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01725282"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "HAM-D17 is to rate the severity of depression in who are already diagnosed as depressed.  The higher the score, the more severe the depression.", 
                "measure": "Hamilton Rating Score for Depression (HAM-D17)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Clinical Global Impressions-Improvement (CGI-I)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Pittsburgh Sleep Quality Index (PSQI)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events, vital signs, 12-lead ECG and labo-tests", 
                "safety_issue": "No", 
                "time_frame": "During the treatment (for 6 weeks) and dose-tapering period (+ 7 days)."
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}